RECRUITINGINTERVENTIONAL
Longitudinal SV2A and MRI in Premanifest HD
Longitudinal Imaging of Striatal Synaptic Density and Volume in People With Premanifest Huntington's Disease.
About This Trial
AIM: to compare the sensitivity of SV2A PET and volumetric MRI to detect longitudinal striatal changes in premanifest HD. DESIGN: The investigators will include late premanifest HD mutations carriers and matched healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 18F-SynVesT-1 PET and volumetric MRI at baseline and after 2 years.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age 20-75 years inclusive.
- Capacity to understand the willing to sign a consent form form.
- HD mutation carriers:
- HTT (CAG)n ≥ 40
- HD-ISS \< 2
- CAP100 score \> 70
Who Should NOT Join This Trial:
- neuropsychiatric diseases (other than HD for HD mutation carriers)
- major internal medical diseases
- white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities
- history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse
- contraindications for MR
- pregnancy
- previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age 20-75 years inclusive.
* Capacity to understand the informed consent form.
* HD mutation carriers:
* HTT (CAG)n ≥ 40
* HD-ISS \< 2
* CAP100 score \> 70
Exclusion Criteria:
* neuropsychiatric diseases (other than HD for HD mutation carriers)
* major internal medical diseases
* white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities
* history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse
* contraindications for MR
* pregnancy
* previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.
Treatments Being Tested
DIAGNOSTIC_TEST
Diagnostic Test: 18F-SynVesT-1 PET
Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
DIAGNOSTIC_TEST
Volumetric MRI
Magnetic resonance imaging of brain volume.
Locations (1)
University Hospitals Leuven
Leuven, Belgium